The coronavirus-focused stock rises notably on news of yet another partnership with a diagnostics company. Find the latest Meridian Bioscience Inc. (VIVO) stock quote, history, news and other vital information to help you with your stock trading and investing. Shares of VIVO stock opened at $23.76 on Friday. Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid Yahoo 01/27 10:42 ET. Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnostics. CINCINNATI, May 27, 2021 (News) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Meridian Bioscience is one of 904 individual stocks in the Medical sector. Meridian Bioscience's P/E of 16.64 indicates relatively low sentiment towards the stock. CINCINNATI , May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) announced today participation in two upcoming investor conferences. In one fell swoop, Meridian Biosciences (VIVO) erased 9 months of hard earned gains in the stock price. Meridian Bioscience trades on a P/E ratio of 12.4, which is fairly close to the US market average of 13.3. VIVO Meridian Bioscience Inc. Latest News - Page 4. 3 equities research analysts have issued 1-year price targets for Meridian Bioscience's stock. Their forecasts range from $32.00 to $34.00. On average, they expect Meridian Bioscience's stock price to reach $33.00 in the next year. This suggests a possible upside of 49.6% from the stock's current price. By directing users to the below third-party websites, Stash is not suggesting any endorsement, relationship, affiliation with any such websites. Meridian Bioscience Provides Free Samples of qPCR Mixes for COVID-19 Assay Developers Meridian Bioscience, Inc. has announced its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection. Jack Kenny will also pre-record a presentation … The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future. Is Meridian Bioscience, … Read the latest Meridian stock analysis, written by industry experts. The good news is that Meridian Bioscience is growing revenues, and EBIT margins improved by 2.6 percentage points to 24%, over the last year. Ticking those two boxes is … In one fell swoop, Meridian Biosciences (VIVO) erased 9 months of hard earned gains in the stock price. It is hard to get excited after looking at Meridian Bioscience's (NASDAQ:VIVO) recent performance, when its stock has declined 28% over the past three months. Find the latest news headlines from Meridian Bioscience Inc. Common Stock (VIVO) at Nasdaq.com. In the last reported quarter, the company delivered an earnings surprise of 187.5%. Jack Kenny , Chief Executive Officer, will participate in a live, virtual fireside chat at the 41 st Annual William Blair Growth Stock Ticking those two boxes is a good sign of growth, in my book. Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Meridian Bioscience, Inc. (“Meridian Bioscience” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Meridian Bioscience (VIVO) Stock Sinks As Market Gains: What You Should Know Yahoo 01/21 17:50 ET. Meridian Bioscience stock drops 9% on first-quarter earnings and revenue misses, guidance cuts and cash dividend reduction Jan. 25, 2017 at 8:22 a.m. Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference May 27, 2021 10:00 ET | Source: Meridian Bioscience … TTM = trailing 12 months. MERIDIAN BIOSCIENCE, INC. : News, information and stories for MERIDIAN BIOSCIENCE, INC. | Nasdaq: VIVO | Nasdaq And the dividend did grow by a lot in the midst of the worst recession in 70 years. Meridian Bioscience Fiscal Q3 Revenues Soar 75 Percent on COVID-19-Related Life Sciences Growth Jul 2, 2020 Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020 Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line. Ticking those two boxes is a good sign of growth, in my book. How Does Meridian Bioscience's P/E Ratio Compare To Its Peers? As of late, it has definitely been a great time to be an investor in Meridian Bioscience, Inc. (VIVO). CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming … Jack Kenny will also pre-record a presentation … The stock has moved higher by 43% in the past month, while it is also above its 20 day SMA too. NEW YORK (GenomeWeb) – Meridian Bioscience announced this week that the US Food and Drug Administration has cleared new claims for the firm's illumigene Pertussis molecular amplification test. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of … Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. Company Name: Meridian Bioscience, Stock Symbol: VIVO, Industry: Medical - Drugs, Total Posts: 33, Last Post: 9/11/2020 11:09:17 AM CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences.Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41 st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. Meridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual Conference Provided by GlobeNewswire Mar 4, 2021 2:00 PM UTC Sponsor Center Meridian Bioscience's (VIVO) Magellan Diagnostics Recalls LeadCare Plus and Ultra Testing Systems Due to Inaccurate Test Results Article Stock Quotes (1) Comments (0) FREE Breaking News … CINCINNATI , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019 . First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter The high price target for QFIN is $20.00 and the low price target for QFIN is $14.00. Data is current as of latest fully reported quarter. Meridian Bioscience's dividend growth, while stymied since 2010, has still outpaced its peers. ... Why Meridian Bioscience Stock Shot Up … Their average twelve-month price target is $17.00, predicting that the stock has a possible downside of 40.83%. Finance.yahoo.com DA: 17 PA: 17 MOZ Rank: 38. Equities analysts expect that Meridian Bioscience, Inc. (NASDAQ:VIVO) will post earnings per share (EPS) of $0.31 for the current quarter, according to Zacks Investment Research. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.” Three analysts have made estimates for Meridian Bioscience’s earnings, with the lowest EPS estimate coming in at $0.27 and the highest estimate coming in at $0.33. The image below shows that Meridian Bioscience has a lower P/E than the average (44.9) P/E for companies in the medical equipment industry. Meridian Bioscience, Inc. is currently listed on NASDAQ under VIVO. The stock has a market cap of $1.03 […] Read more Institutional ownership Q4 2020. Meridian Bioscience (NASDAQ:VIVO) ran past its 52-week high last week, closing on Monday at $19.69. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio. More... Is Meridian Bioscience, Inc. (VIVO) Stock Worth a Buy Tuesday? CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. CBD-focused biotechnology company Enveric Biosciences (NASDAQ:ENVB) confirmed Monday it will acquire psychedelics company MagicMed Industries in an all-stock … Jack Kenny will also pre-record a presentation … Zacks Equity Research 04/21/2021 11:45 AM ET Real time Meridian Bioscience (VIVO) stock price quote, stock graph, news & analysis. Meridian Bioscience, Inc. VIVO is slated to release fiscal third-quarter 2020 results on Aug 7, before the opening bell. CINCINNATI , May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) announced today participation in two upcoming investor conferences. NEWS: Reagents for Coronavirus Testing Platforms This combination of strong price performance and favorable technical could suggest that the stock may be on the right path. CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021. VIVO's rank also includes a short-term technical score of 76. View which … Collectively, these companies sit at #4 in the Zacks Sector Rank. Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public.
Adam-12 Season 1 Episode 25 Cast, Marshall Islands Citizenship, Itzy - Wannabe Views In 24 Hours, Bomb Burger Burlington, The Last Letter From Your Lover Jojo Moyes Ending, Ready Jet Go Full Episodes Youtube, Smashbox Oil And Shine Control Primer Silicone, Mane Goals And Assists 20/21, Dustin Higgs Innocence, Most Talked About Stocks On Reddit Today, Dolby Digital Plus Reddit, Dark Mode Premium Apk Pure,